Glyxambi CV Risk Protection Tools & Apps 5 years of EMPA-REG Outcome Let's Talk Prof Christoph Wanner’s take on EMPA-KIDNEY Prescribing Information Voice of CRM Videos Previous Next Voice of CRM Read more 1:15 PEKP||Primary Care Physicians to Transform CKD Prognosis Watch now Opens in new tab Read more 1:25 PEKP||EMPA-KIDNEY: Benefits of Empagliflozin for A1 & A2 Watch now Opens in new tab Read more 1:12 PEKP||Synergistic Relationship between RAASi and SGLT2i Watch now Opens in new tab Read more 1:31 PEKP||Optimize RAASi Dose with SGLT2i Watch now Opens in new tab Read more 1:06 PEKP||The Role of Screening in CKD Patient Outcomes Watch now Opens in new tab Read more 1:09 PEKP||Initiating SGLT2i in Low eGFR Patients Watch now Opens in new tab Pagination Load more